TNFSF11 and cancer: Bone-modifying agents (BMAs), zoledronic acid (ZA) and denosumab (the monoclonal antibody directed against RANKL) used for BoM patients has been commonly applied to restrain cancer-related pain, the progression of bone focus zone, and ensuing SREs.